<DOC>
	<DOCNO>NCT02577003</DOCNO>
	<brief_summary>This study ass safety efficacy addition ipragliflozin daily Japanese participant Type 2 diabetes mellitus ( T2DM ) inadequate glycemic control sitagliptin , diet , exercise therapy . The primary hypothesis study addition ipragliflozin compare placebo provide great reduction hemoglobin A1C ( HbA1c ) assess change baseline Week 24 .</brief_summary>
	<brief_title>Double-blind Ipragliflozin Add-on Study Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Sitagliptin ( MK-0431J-843 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes mellitus Inadequate glycemic control diet/exercise therapy sitagliptin monotherapy HbA1c ≥7.0 % ≤10.0 % study participation History Type 1 diabetes mellitus history ketoacidosis History follow medication : thiazolidinediones ( TZD ) and/or insulin within 12 week prior study participation sodium glucose cotransporter 2 ( SGLT2 ) inhibitor anytime Currently urinary tract infection genital infection subjective symptom</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>